Lv33
294 积分 2023-03-18 加入
Structure-Activity Relationship Guided Scaffold Hopping Resulted in the Identification of GLPG4970, a Highly Potent Dual SIK2/SIK3 Inhibitor
4小时前
已完结
Experimental and investigational phosphodiesterase inhibitors in development for asthma
4天前
已完结
Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases
4天前
已完结
Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy
4天前
已完结
Phosphodiesterase inhibitors in airways disease
4天前
已完结
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
5天前
已完结
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
5天前
已完结
Exploring dual PDE3/4 inhibition in the treatment of airway diseases
5天前
已完结
Ensifentrine, a dual PDE3/PDE4 inhibitor, improves FEV1 regardless of smoking status or history of chronic bronchitis
5天前
已关闭
The need for inhaled phosphodiesterase inhibitors in chronic obstructive pulmonary disease
5天前
已完结
皖公网安备34019202002308
